Association Between SGLT2 Inhibitor Treatment and Diabetic Ketoacidosis and Mortality in People With Type 2 Diabetes Admitted to Hospital With COVID-19.

Saved in:
Bibliographic Details
Title: Association Between SGLT2 Inhibitor Treatment and Diabetic Ketoacidosis and Mortality in People With Type 2 Diabetes Admitted to Hospital With COVID-19.
Authors: Khunti, Kamlesh, Ruan, Yue, Davies, Jim, Field, Benjamin C.T., Harris, Sophie, Kosiborod, Mikhail, Nagi, Dinesh, Narendran, Parth, Patel, Dipesh, Ryder, Robert E.J., Várnai, Kinga A., Wild, Sarah H., Wilmot, Emma G., Rea, Rustam, ReaRustamWilmotEmmaKhuntiKamleshWildSarahFieldBenNarendranParthGandhiRajivHarrisSophieNagiDineshRyderRobertDaviesJimHarrisSteveFreemanOliverMaylorBenVárnaiKinga A.RoadknightGailCullMelissaRuanYueEdwardsAmyGeldingSusanGunganahKirunAungPyeiBanerjeeMoul, Wilmot, Emma, Wild, Sarah, Field, Ben, Gandhi, Rajiv, Ryder, Robert, et al
Source: Diabetes care Dec2022; Vol. 45 (12).
Journal Info: Publisher: American Diabetes Association ISSN: 0149-5992
Database: MEDLINE Ultimate
Description
ISSN:1935-5548
DOI:10.2337/dc22-0357